Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors

Morais, Helen de; Souza, Camila Pasquini de; Silva, Luisa M. da; Ferreira, Daniele Masterson Tavares Pereira; Baggio, Cristiane Hatsuko; Vanvossen, Ana Carolina; Carvalho, Milene Cristina de; Silva-Santos, José Eduardo da; Bertoglio, Leandro J.; Cunha, Joice Maria da; Zanoveli, Janaína Menezes

doi:10.1016/j.euroneuro.2016.08.007

Cited by 36 publications

(24 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high tissue content of OEA in the hippocampus is in agreement with a previous study indicating that its oral administration induces antidepressant effects associated with the regulation of brain-derived neurotrophic factor levels in the hippocampus (Jin et al, 2015). On the other hand, decreased levels of AEA are associated with depression (Vinod et al, 2012) and anxiogenic effects (Rubino et al, 2008), whereas its augmentation reverses depressive-like responses through the activation of CB 1 Rs (de Morais et al, 2016). It is possible that the higher levels of AEA in the temporal neocortex and OEA in the hippocampus of patients with MTLE avoid the comorbid A/D.…”

Section: Discussionsupporting

confidence: 91%

Endocannabinoid System and Cannabinoid 1 Receptors in Patients With Pharmacoresistant Temporal Lobe Epilepsy and Comorbid Mood Disorders

Rocha¹,

Çınar

Guevara‐Guzmán

et al. 2020

Front. Behav. Neurosci.

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Endocannabinoid System and Cannabinoid 1 Receptors in Patients With Pharmacoresistant Temporal Lobe Epilepsy and Comorbid Mood Disorders

Rocha¹,

Çınar

Guevara‐Guzmán

et al. 2020

Front. Behav. Neurosci.

View full text Add to dashboard Cite

“…This is in line with previous results reporting a positive correlation between 2-AAG and depression scores in pain patients (La Porta, et al, 2015). In addition, a recent study on rats showed that low doses of AEA were successful in reversing depression-like behaviors (de Morais, et al, 2016). The altered levels of AEA could therefore be a factor contributing to the high rates of comorbidity between AN and depressive disorders.…”

Section: -Arachidonoylglycerol (2-ag)supporting

confidence: 91%

Altered circulating endocannabinoids in anorexia nervosa during acute and weight‐restored phases: A pilot study

Piccolo

Claussen

Bluemel

et al. 2019

Euro Eating Disorders Rev

View full text Add to dashboard Cite

Anorexia nervosa (AN) is an eating disorder characterized by a low food intake and often exceeding exercise, leading to a particularly low body × weight proportion. Patients with AN usually report less hunger than healthy controls. Endogenous endocannabinoids (eCBs), specifically the anandamide, have been associated to hunger, as a meal initiator, but research regarding AN and eCB and inconclusive. In this pilot study, we investigated plasma levels of eCB in inpatients with AN during fasting and after eating, both during the acute AN phase and after weight recovery. After an 8-hr fasting period, blood sample was collected from all participants. After that, participants were given a muffin test meal. Blood samples for the investigation of endogenous eCBs anandamide (N-arachidonoylethanolamide [AEA]) and 2-arachidonoylglycerol (2-AG) were then collected after 120 and 240 min. Participants were only allowed to eat and drink what was offered them during the research. AN reported less hunger than controls during fasting and at the end of the experiment. Also, plasma levels of AEA were significantly smaller in AN in comparison with controls in all time points. No significant difference was found for 2-AG plasma levels. After recovery, no significant difference was found for eCB levels. These findings could be interpreted as an AEA deregulation in AN before and after food intake, which persists after weight recovery. These findings may have implications to the pharmacological treatment of AN and to relapse occurring in the disorder.

show abstract

“…The induction of experimental type-1 diabetes mellitus was performed following an overnight fasting period and four weeks before the start of the pharmacological treatment, as described in detail elsewhere [47]. Briefly, animals received a single intraperitoneal injection of streptozotocin (STZ) (60 mg/kg body weight; Sigma-Aldrich, St. Louis, USA) dissolved in citrate buffer (0.1 M, pH 4.5) (DIAB) as described elsewhere [47,48]. Control animals were injected with citrate buffer (SHAM) alone.…”

Section: Induction Of Experimental Type-1 Diabetesmentioning

confidence: 99%

“…In the present study, diabetic animals displayed depressivelike behaviour in the FST. The association between chronic PDN and the development of emotional disorders is well established in patients [88,89] and rats [48,90]. In the rat, the attempt at controlling diabetes-induced depressive-like behaviour has been explored using several drugs including antidepressants such as fluoxetine [91] and imipramine [92], antioxidants such as N-acetylcysteine [93] and endocannabinoids such as anandamide [48] among others.…”

Section: Minocycline In the Control Of Diabetes-associated Emotional mentioning

confidence: 99%

Minocycline reduces mechanical allodynia and depressive-like behaviour in type-1 diabetes mellitus in the rat

Amorim

Puga

Bragança

et al. 2017

Behavioural Brain Research

View full text Add to dashboard Cite

A common and devastating complication of diabetes mellitus is painful diabetic neuropathy (PDN) that can be accompanied by emotional disorders such as depression. A few studies have suggested that minocycline that inhibits microglia may attenuate pain hypersensitivity in PDN. Moreover, a recent study reported that minocycline has an acute antidepressive-like effect in diabetic animals. Here we studied whether (i) prolonged minocycline treatment suppresses pain behaviour in PDN, (ii) the minocycline effect varies with submodality of pain, and (iii) the suppression of pain behaviour by prolonged minocycline treatment is associated with antidepressive-like effect. The experiments were performed in streptozotocin-induced rat model of type-1 diabetes. Pain behaviour was evoked by innocuous (monofilaments) and noxious (paw pressure) mechanical stimulation, innocuous cold (acetone drops) and noxious heat (radiant heat). Depression-like behaviour was assessed using forced swimming test. Minocycline treatment (daily 80mg/kg per os) of three-week duration started four weeks after induction of diabetes. Diabetes induced mechanical allodynia and hyperalgesia, cold allodynia, heat hypoalgesia, and depression-like behaviour. Minocycline treatment significantly attenuated mechanical allodynia and depression-like behaviour, while it failed to produce significant changes in mechanical hyperalgesia, cold allodynia or heat hypoalgesia. The results indicate that prolonged per oral treatment with minocycline has a sustained mechanical antiallodynic and antidepressive-like effect in PDN. These results support the proposal that minocycline might provide a treatment option for attenuating sensory and comorbid emotional symptoms in chronic PDN.

show abstract

Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors

Cited by 36 publications

References 64 publications

Endocannabinoid System and Cannabinoid 1 Receptors in Patients With Pharmacoresistant Temporal Lobe Epilepsy and Comorbid Mood Disorders

Endocannabinoid System and Cannabinoid 1 Receptors in Patients With Pharmacoresistant Temporal Lobe Epilepsy and Comorbid Mood Disorders

Altered circulating endocannabinoids in anorexia nervosa during acute and weight‐restored phases: A pilot study

Minocycline reduces mechanical allodynia and depressive-like behaviour in type-1 diabetes mellitus in the rat

Contact Info

Product

Resources

About